Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

Tania Marusia Capusan, M. Herrero‐Moyano, C. Martínez-Mera, Al Walid Freih-Fraih, E. Daudén

JAAD Case Reports · 2018 · 23 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

Secukinumab (SEK), a fully human anti–interleukin (IL)-17A monoclonal antibody, is effective in the treatment of psoriasis. Although it has a favorable safety profile, 2 cases of associated oral lichen planus (OLP)/lichenoid mucositis have been recently described.1,2

References

3